Английская Википедия:Balcinrenone
Материал из Онлайн справочника
Шаблон:Short description Шаблон:Orphan Шаблон:Infobox drug
Balcinrenone is an experimental selective mineralocorticoid receptor modulator developed by AstraZeneca for heart failure. Compared to mineralocorticoid receptor antagonists, it is hoped to have less effect on electrolytes and therefore a lower risk of hyperkalemia.[1][2][3][4][5]
References